Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-524
Closed -$474K 35
2024
Q2
$474K Buy
524
+12
+2% +$9.6K 1.16% 31
2024
Q1
$398K Buy
512
+4
+0.8% +$2.85K 1.06% 34
2023
Q4
$296K Buy
508
+13
+3% +$7.59K 0.84% 36
2023
Q3
$266K Sell
495
-6
-1% -$3.09K 0.2% 85
2023
Q2
$235K Sell
501
-689
-58% -$289K 0.05% 162
2023
Q1
$409K Sell
1,190
-129
-10% -$43.5K 0.08% 154
2022
Q4
$479K Sell
1,319
-308
-19% -$109K 0.1% 146
2022
Q3
$526K Buy
1,627
+175
+12% +$55.4K 0.11% 138
2022
Q2
$470K Buy
1,452
+229
+19% +$68.7K 0.1% 148
2022
Q1
$350K Buy
1,223
+24
+2% +$6.18K 0.06% 199
2021
Q4
$331K Buy
+1,199
New +$304K 0.07% 190

Other funds holding LLY

TCWP's LLY Position: Q3 2024 in Review

TCWP sold out of Eli Lilly (LLY) in Q3 2024, closing a stake of 524 shares — an estimated $474K sold.

TCWP first reported a position in LLY in Q4 2021 and held it in 11 quarters. The position peaked at $526K in Q3 2022. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

  • TCWP reported no remaining Eli Lilly position as of Q3 2024 after selling out during the quarter.
  • TCWP sold 524 Eli Lilly shares in Q3 2024, an estimated $474K.
  • TCWP first reported a position in Eli Lilly in Q4 2021 and held it in 11 quarters.
  • TCWP's Eli Lilly position peaked at $526K in Q3 2022.
  • 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on TCWP's 13F filing for Q3 2024.